Bruker Corporation · NASDAQ:BRKR
Bruker — J.P. Morgan 43rd Annual Healthcare Conference 2025
20 slides from Bruker's conference presentation, Jan 13, 2025
Slide 1: Built For The Future – Our Transformation Story
Built For The Future – Our Transformation Story BRUKER 2025 Leadership in the Post-Genomic Era Frank H. Laukien Chairman, President & CEO Bruker Corporation (Nasdaq: BRKR) 2025 JP Morgan Healthcare Conference San Francisco, CA | January 13, 2025 INNOVATION WITH INTEGRIT Y
Slide 2: Safe Harbor Statement
BRUKER CORPORATION Safe Harbor Statement Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
Slide 3: Bruker has executed a successful multiyear transformation
Bruker has executed a successful multiyear transformation into a Growth-Oriented Industry Leader with very attractive margin opportunities. 3
Slide 4: Key Takeaways on our Multiyear Transformation
IN N OVATION WITH IN TEG RIT Y Key Takeaways on our Multiyear Transformation Track Record of Performance Execution ▪ Attained Scale: 70% Cumulative Revenue Growth in Last 4 Years to >$3.3B (15% CER CAGR) ▪ Profit Expansion: Achieved ~1000 bps Operating Margin Increase in 8 Years1 with 15% EPS CAGR B
Slide 5: Strategic, Visionary, and Disciplined M&A
BRUKER’S TRAN SF ORM A T ION IN TO A F AST GROWTH COMP ANY Strategic, Visionary, and Disciplined M&A: Accelerating Growth, Attaining Scale, Establishing Base for Next 1000 bps OM Expansion Strategic 1. Add life-science and biopharma 2. Enter very large TAMs with 3. Attractive valuations rationale so
Slide 6: Strategic M&A | BNANO Group
Strategic M&A | BNANO Group SPATIAL BIOLOGY & CELLULAR ANALYSIS “Single-cell and Spatial Biology are fundamental to our understanding Acquired May 2024 of disease in this new era of biology.” BNANO Group President Mark Munch Acquired October 2023 ✓ NanoString now combined with Canopy and Bruker Spat
Slide 7: Strategic M&A | CALID Group
Strategic M&A | CALID Group CLINICAL MICROBIOLOGY & INFECTION DIAGNOSTICS “With ELITech MDx and our leading MALDI Biotyper, we are now a formidable force in infectious Acquired April 2024 disease diagnostics.” CALID Group President Juergen Srega ✓ >1,400 installed S2A systems ➔ 145 new systems in FY
Slide 8: Strategic M&A | BioSpin Group
Strategic M&A | BioSpin Group NEXT-GEN LAB AUTOMATION, DIGITIZATION FOR AI “Integrated automation and software for R&D and QC are Acquired March 2024 foundational for AI-augmented ‘self-driving’ labs.” Over 25 Years of Lab Automation BioSpin Group President Falko Busse ✓ Modular automation for R&D a
Slide 9: Drivers of the Life-Science Tools Industry
What’s Next? Some 2000-2024 Perspectives Drivers of the Life-Science Tools Industry ▪ China was the major growth driver ▪ Biopharma R&D bolus during pandemic ▪ Minor innovations and replacement cycles created value ▪ Draft human genome in 2000 ushered in 25 years of genomic value generation ▪ Focus
Slide 10: Trends for the Next 25 Years
…and the Future will be different: Trends for the Next 25 Years ▪ After the stimulus, China’s role as a key growth driver is unclear ▪ Biopharma R&D will rebound – but at rational levels ▪ Nanoscience tools are key to enable AI technology advancements ▪ Genome Biology is foundational and ubiquitous
Slide 11: The Vast Complexity of Phenome Biology Creates Enormous Opportunities for Bruker
The Vast Complexity of Phenome Biology Creates Enormous Opportunities for Bruker ▪ Proteomics & Multiomics are Central ▪ Spatial Context & Single-Cell Biology a Must ▪ Structures, Interactomes & Function are Key © 2025 Bruker J.P. Morgan Healthcare Conference | January 13, 2025 | 11
Slide 12: Positioned for the Post-Genomic Era
BRUKER’S TRAN SF ORM A T ION IN TO A F AST GROWTH COMP ANY Positioned for the Post-Genomic Era Understanding the Hierarchy of Complexity in Biology “Bruker has transformed itself for Leadership in the Post-Genomic Era. Our differentiated Life-Science Tools enable the exploration Post-Genomic Era of
Slide 13: Bruker 2025 is Built For The Future
BRUKER’S TRAN SF ORM A T ION IN TO A F AST GROWTH COMP ANY Our Transformation Story Bruker 2025 is Built For The Future Pivot to Higher Growth, Higher Margin Opportunities Performance Execution Thriving Core is our Foundation Disciplined Entrepreneurialism ▪ Leading infectious disease MDx franchise
Slide 14: ‘What’s in Your Portfolio?’
IN N OVATION WITH IN TEG RIT Y ‘What’s in Your Portfolio?’ Track Record of Performance Execution ▪ Attained Scale: 70% Cumulative Revenue Growth in Last 4 Years to >$3.3B (15% CER CAGR) ▪ Profit Expansion: Achieved ~1000 bps Operating Margin Increase in 8 Years1 with 15% EPS CAGR Positioned for Lead
Slide 15: Because the Future will be Different…
Because the Future will be Different…
Slide 16: APPENDIX
IN N OVATION WITH IN TEG RIT Y 2025 J.P. Morgan Healthcare Conference APPENDIX © 2024 Bruker J.P. Morgan Healthcare Conference | January 13, 2025 | 16
Slide 17: Performance Execution Driving Revenue and Non-GAAP EPS Growth
BRUKER’S TRAN SF ORM A T ION IN TO A G ROWTH -ORIEN TE D COMP ANY Performance Execution Driving Revenue and Non-GAAP EPS Growth Continued Track Record of Performance Performance Execution Revenue 9% Organic Non-GAAP 13% Non- Revenue GAAP diluted CAGR Diluted EPS EPS CAGR1 ▪ Bruker Management Process
Slide 18: Reconciliation of GAAP Reported Revenue Growth to Organic Revenue Growth
BRUKER’S TRAN SF ORM A T ION IN TO A G ROWTH -ORIEN TE D COMP ANY Reconciliation of GAAP Reported Revenue Growth to Organic Revenue Growth [$M] 2019 2020 2021 2022 2023 Revenue as of the prior $1,895.6 $2,072.6 $1,987.5 $2,417.9 $2,530.7 comparable period Non-GAAP components: Acquisitions and divest
Slide 19: Reconciliation of GAAP and Non-GAAP Operating Income
BRUKER’S TRAN SF ORM A T ION IN TO A G ROWTH -ORIEN TE D COMP ANY Reconciliation of GAAP and Non-GAAP Operating Income [$M] 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 GAAP Operating Incom e $106.0 $160.2 $181.8 $219.5 $262.4 $300.9 $248.3 $413.3 $432.7 $436.9 Non-GAAP adjustments: Restructuri
Slide 20: Reconciliation of GAAP and Non-GAAP Earnings Per Share (Diluted)
BRUKER’S TRAN SF ORM A T ION IN TO A G ROWTH -ORIEN TE D COMP ANY Reconciliation of GAAP and Non-GAAP Earnings Per Share (Diluted) [$] 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 GAAP Earnings Per Share (D iluted) $0.33 $0.60 $0.95 $0.49 $1.14 $1.26 $1.02 $1.81 $1.99 $2.90 Non-GAAP adjustments
Bruker — J.P. Morgan 43rd Annual Healthcare Conference 2025 on 6ix